Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.78 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.78 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046848 | 0.88 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1G6PD | |
| SCHEMBL4740712 | 0.88 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1G6PD | |
| SCHEMBL1305315 | 0.86 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1 | |
| SCHEMBL4784916 | 0.86 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL4784799 | 0.85 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL4743521 | 0.85 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL14777477 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL1865482 | 0.84 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1 | |
| SCHEMBL4786600 | 0.84 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL1304392 | 0.83 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008103353-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | claimed |
| WO-2008103353-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008103353-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885G6PD 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.